|
|
 |
|
Viewing report
|
|
|
|
Thought Leader Insight & Analysis Report: Alzheimer’s Disease Q2 2010
Medpredict, May 2010, Pages: 143
Thought leaders who treat Alzheimer’s disease face multiple challenges in their effort to improve the lives of patients who have or will have dementia. Just as a cardiologist would do to prevent a heart attack in a patient with high blood pressure and high cholesterol, the neurologist or gerontologist must be able to identify people who are at risk of developing mild cognitive impairment and progressing on to Alzheimer’s disease, and treat them prophylactically. For patients with more advanced disease, new therapies are needed to slow degeneration, enhance cognitive function and protect the remaining neuronal structure. For both symptomatic and asymptomatic patients, diagnostics are needed to track the effectiveness of these new therapeutics.
In this report, MedPredict’s experts describe the clinical progress of the most interesting therapeutic and diagnostic candidates in achieving these goals. The Panel covers active and passive immunologic approaches that hold promise in prevention of Alzheimer’s disease and treatment at the earliest stages of dementia. They rank the most promising small molecules and antibodies that are targeting amyloid and plaques, offering their opinions on ?-secretase inhibitors and modulators, ß-secretase inhibitors, Tau inhibitors, cardiovascular agents, anti-amyloids and aggregation inhibitors, mTOR inhibitors, SIRT-1, Liver X, metal chelators and drugs specifically designed to enhance mental function.
As part of this Panel we asked our Thought Leaders to engage in a thought exercise to designate their “fantasy formulary”, comprised of the top seven therapeutics, currently in the development pipeline, that they want to see available for use. The Panel’s responses are just as enlightening regarding what they would NOT put on their fantasy formularies. This is the second year we’ve conducted this exercise and we provide both years’ results for comparison. The other aims of this Panel were to review progress in the development of diagnostics and imaging technology, and to help shed light on current and future reimbursement policy.
Product samples
A sample for this product is available. Please Login/Register to download this sample.
|
|
|
|
